CytoDyn to Present at Wall Street Reporter’s “NEXT SUPER STOCK Live” Conference on 1/23/2020 at 12:30 pm ET/ 9:30 am PTJoin the livestream presentation here

Investor Relations

Latest Presentation

Upcoming Event

CROI Meeting

Mar 8 – Mar 11, 2020

Latest Financial Results

Q2 2020

Quarter Ended Nov 30, 2019

Latest Annual Filing

For Year Ending May 31, 2019

Email Alerts

Stay informed and receive company updates straight to your inbox

Sign up today

Company Overview

CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor.  CCR5 appears to play a key role in the ability of HIV to enter and infect healthy T-cells.  The CCR5 receptor also appears to be implicated in tumor metastasis and in immune-mediated illnesses, such as graft-vs-host disease (GvHD) and NASH.

Investor Contact Information

Company

CytoDyn Inc.
1111 Main Street
Suite 660
Vancouver, WA 98660
T: 360-980-8524
F: 360-980-8549
info@cytodyn.com

Transfer Agent

Computershare
c/o Shareholder Services
P.O. Box 505002
Louisville, KY 40233-5002
T: 800-962-4284